Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Investigational COVID-19 Vaccine 2
- Development stage
- Unknown
- Lead developer
- Moderna
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Injection
01
Overview
Investigational COVID-19 Vaccine 2 is a sterile liquid for injection, developed by ModernaTX, Inc. It is an mRNA-based vaccine being evaluated in a Phase 1/2 clinical trial for its safety, reactogenicity, and immunogenicity against SARS-CoV-2.
Beyond the preview
Go deeper on Investigational COVID-19 Vaccine 2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Investigational COVID-19 Vaccine 2.